Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02992522
Title Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Beth Christian
Indications

follicular lymphoma

B-cell lymphoma

Therapies

Lenalidomide + Obinutuzumab + Venetoclax

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Emory University Atlanta Georgia 30322 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field